drugset / Trial / NCT00842595
Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of the protocol is to estimate the complete response rate of three courses of the association of rituximab, navelbine, ifosfamide, mitoxantrone, and prednisone in relapsed aggressive non hodgkin's B-cell lymphoma
Timeline
- Start
- 2003-12
- Primary completion
- 2009-11
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ifosfamide | Small molecule | 1000 mg/m2 | — |
| Subject | Mitoxantrone | Small molecule | 10 mg/m2 | Intravenous |
| Subject | Prednisone | Other / unclassified | — | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Vinorelbine | Small molecule | 25 mg/m2 | Intravenous |